1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off
TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at...
/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is...
Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared...
Regeneron Pharmaceuticals has outperformed the broader market over the past year, and analysts remain highly upbeat about the stock’s growth potential.
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved,...
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges
TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference...